Repligen Corp (RGEN) Stock Price, Quote & News

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale co...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 781 250 0111

Fax: 781 250 0115

Website: www.repligen.com

Address:

Building 1, Suite 100 41 Seyon Street, Waltham, United States

Iightning Dec. 4 at 8:52 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $170C Entry: 4.10 Exit: 6.22 Return: +51.82% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BillionerOfKing Dec. 4 at 2:46 PM

$RGEN Current Stock Price: $163.60 Contracts to trade: $165 RGEN Dec 19 2025 Call Entry: $5.62 Exit: $9.99 ROI: 78% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Iightning Dec. 4 at 4:34 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $170C Entry: 4.22 Exit: 5.33 Return: +26.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 8:58 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $120C Entry: 33.55 Exit: 54.81 Return: +63.38% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 10:46 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RGEN **Contract:** Dec 19 $170C **Entry:** 6.47 **Exit:** 9.26 **Return:** **+42.94% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Estimize Nov. 27 at 11:00 AM

Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

c2rshi2r Nov. 26 at 7:50 PM

$RGEN https://www.marketbeat.com/instant-alerts/rep-lisa-c-mcclain-sells-repligen-corporation-nasdaqrgen-stock-2025-11-25/

0 · Reply

Iightning Nov. 26 at 1:33 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 11:39 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:35 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 26, 2025, 7:30 AM EST - 8 days ago

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 18, 2025, 2:48 PM EST - 16 days ago

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 18, 2025, 11:18 AM EST - 16 days ago

Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 14, 2025, 3:28 AM EST - 20 days ago

Repligen: Rare Growth In The Biopharma Supplies Industry

Nov 11, 2025, 3:11 PM EST - 23 days ago

Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 10, 2025, 1:41 PM EST - 24 days ago

Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Oct 28, 2025, 5:01 PM EDT - 5 weeks ago

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:30 AM EDT - 5 weeks ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 15, 2025, 7:30 AM EDT - 7 weeks ago

Repligen to Report Third Quarter 2025 Financial Results

Sep 25, 2025, 11:37 AM EDT - 2 months ago

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 10:32 AM EDT - 3 months ago

Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Aug 22, 2025, 7:30 AM EDT - 3 months ago

Repligen Corporation to Present at Upcoming September Conferences

Aug 14, 2025, 3:24 PM EDT - 4 months ago

Repligen Corporation: Still Navigating Through The Covid Cliff

Jul 31, 2025, 10:45 AM EDT - 4 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 29, 2025, 5:31 PM EDT - 4 months ago

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:30 AM EDT - 4 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Repligen to Report Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 6 months ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

May 27, 2025, 7:30 AM EDT - 6 months ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 7, 2025, 7:30 AM EDT - 7 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Apr 29, 2025, 12:58 PM EDT - 7 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Repligen Reports First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 8 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Mar 20, 2025, 7:52 AM EDT - 9 months ago

Repligen: Ongoing Bioprocessing Market Recovery

Mar 4, 2025, 1:26 PM EST - 9 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Mar 4, 2025, 7:30 AM EST - 9 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Feb 20, 2025, 2:53 PM EST - 10 months ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:00 PM EST - 10 months ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 20, 2025, 11:25 AM EST - 10 months ago

Repligen's Q4 Slightly Tops Expectations

Feb 11, 2025, 7:30 AM EST - 10 months ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Jan 7, 2025, 7:30 AM EST - 11 months ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:30 AM EST - 11 months ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Nov 12, 2024, 3:07 PM EST - 1 year ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:19 PM EST - 1 year ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Nov 12, 2024, 6:36 AM EST - 1 year ago

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 5, 2024, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at Upcoming Investor Conferences

Oct 14, 2024, 11:15 AM EDT - 1 year ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Aug 23, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 16, 2024, 11:46 AM EDT - 1 year ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Aug 2, 2024, 7:09 AM EDT - 1 year ago

Here's Why Shares in This Hot Healthcare Stock Surged This Week

Jul 31, 2024, 2:50 PM EDT - 1 year ago

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

Jul 30, 2024, 3:03 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 12:01 PM EDT - 1 year ago

Repligen Lowers Guidance On China Weakness, Analyst Expects

Iightning Dec. 4 at 8:52 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $170C Entry: 4.10 Exit: 6.22 Return: +51.82% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BillionerOfKing Dec. 4 at 2:46 PM

0 · Reply

Iightning Dec. 4 at 4:34 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $170C Entry: 4.22 Exit: 5.33 Return: +26.23% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 8:58 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RGEN Contract: Dec 19 $120C Entry: 33.55 Exit: 54.81 Return: +63.38% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 10:46 PM

0 · Reply

Estimize Nov. 27 at 11:00 AM

Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

c2rshi2r Nov. 26 at 7:50 PM

$RGEN https://www.marketbeat.com/instant-alerts/rep-lisa-c-mcclain-sells-repligen-corporation-nasdaqrgen-stock-2025-11-25/

0 · Reply

Iightning Nov. 26 at 1:33 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 11:39 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:35 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $170 Call | Enter: $5.99 Exit: $8.80 | Profit: 46.93% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 9:52 PM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $155 Call | Enter: $6.28 Exit: $8.13 | Profit: 29.55% ROI | https://1ightning.com

0 · Reply

stockpicker63 Nov. 21 at 3:25 PM

Watch today $RGEN, $VFC and $INTU

0 · Reply

Iightning Nov. 21 at 12:59 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $155 Call | Enter: $6.28 Exit: $8.13 | Profit: 29.55% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:28 PM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $155 Call | Enter: $6.28 Exit: $8.13 | Profit: 29.55% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 6:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $RGEN Dec 19 $155 Call | Enter: $6.28 Exit: $8.13 | Profit: 29.55% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 9 at 11:02 PM

$RGA $RGEN $RGLD $RGTU $RKLB

0 · Reply

BEATOFtheMARKET Nov. 6 at 4:56 PM

$RGEN $RGLD $RGTU $RKLB $RL

1 · Reply

BEATOFtheMARKET Nov. 6 at 4:55 PM

$RCL $RDDT $RGEN $RFV $RGA

0 · Reply

BEATOFtheMARKET Oct. 29 at 7:29 PM

$QCOM $QBTX $RGEN $RGTU CYCLE TRADING SIGNAL PLUGGED INTO AI 🔥 LISTS 🔥

0 · Reply

ZacksResearch Oct. 29 at 5:19 PM

$RGEN beats earnings — but the stock drops anyway. Revenue surged year over year and Q3 results topped estimates, yet shares slid as tighter EPS guidance cooled the bullish momentum. Full breakdown here 👉 https://www.zacks.com/stock/news/2780407/rgens-q3-earnings-beat-estimates-revenues-surge-yy-stock-down?cid=sm-stocktwits-2-2780407-teaser-18313&ADID=SYND_STOCKTWITS_TWEET_2_2780407_TEASER_18313

0 · Reply

ZacksResearch Oct. 29 at 3:56 PM

$RGEN beats Q3 earnings but shares drop 5.9%! 🤔 Despite surpassing the Zacks Consensus Estimate with 46 cents per share and a 22% year-over-year revenue spike, concerns over tighter EPS guidance might have dampened investor sentiment. 📉 Check out the full analysis here 👉 https://www.zacks.com/stock/news/2780407/rgens-q3-earnings-beat-estimates-revenues-surge-yy-stock-down?cid=sm-stocktwits-2-2780407-body-18257&ADID=SYND_STOCKTWITS_TWEET_2_2780407_BODY_18257

0 · Reply

AStrokeOfLuck Oct. 28 at 12:16 PM

$RGEN

0 · Reply

Market Cap	9.29B
Revenue (ttm)	634.44M
Net Income (ttm)	-25.51M
EPS (ttm)	N/A
PE Ratio	100.21
Forward PE	99.83
Profit Margin	-4.02%
Debt to Equity Ratio	0.00

Volume	599,100
Avg Vol	979,030
Day's Range	N/A - N/A
Shares Out	56.29M
Stochastic %K	63%
Beta	1.11
Analysts	Strong Sell
Price Target	$185.65